Advertisement

Lycopene increases metabolic activity of rat liver CYP2B, CYP2D and CYP3A

  • Kristýna Nosková
  • Gabriela Dovrtělová
  • Ondřej Zendulka
  • Markéta Strakošová
  • Ondřej Peš
  • Jan JuřicaEmail author
Article
  • 12 Downloads

Abstract

Background

Lycopene as a naturally occurring carotenoid is a common part of the human diet. Several beneficial properties of lycopene have been identified, with the most studied being anti-cancer and antioxidant activity. However, no evidence of possible drug–drug or drug–food supplement interactions has been found.

Methods

We studied the in vivo effect of lycopene on the selected rat liver cytochromes P450 (CYPs): CYP1A2, CYP2B, CYP2C11, CYP2C6, CYP2D, and CYP3A. Lycopene was administered to rats intragastrically at doses of 4, 20, and 100 mg/kg/day for 10 consecutive days. Total protein content, P450 Content, and metabolic activity of selected CYPs were evaluated in the rat liver microsomal fraction.

Results

Increased CYP2B, CYP2D, and CYP3A metabolic activities were observed in animals treated with the lycopene dose of 100 mg/kg/day. The content of CYP3A1 protein was increased by the dose of 100 mg/kg/day and CYP3A2 protein was increased by all administered doses of lycopene.

Conclusion

The results of our study indicate that lycopene increased the metabolic activity of enzymes that are orthologues to the most clinically important human enzymes involved in xenobiotic metabolism. The risk of pharmacokinetic interactions between lycopene dietary supplements and co-administered drugs should be evaluated.

Graphic abstract

Keywords

Lycopene Rat Cytochrome P450 CYP3A Induction 

Notes

Acknowledgements

This publication was written with the support of the Specific University Research grant (MUNI/A/1550/2018) provided by the Ministry of Education, Youth and Sports of the Czech Republic and by the Specific University Research Grant (MUNI/A/0976/2018) and by the funds from the Faculty of Medicine, Masaryk University junior researcher Ondrej Pes.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr. 2000;19(5):563–9.CrossRefGoogle Scholar
  2. 2.
    Chasse GA, Mak ML, Deretey E, Farkas I, Torday LL, Papp JG, et al. An ab initio computational study on selected lycopene isomers. J Mol Struct Theochem. 2001;571(1):27–37.CrossRefGoogle Scholar
  3. 3.
    O’Neill ME, Southon S, Corridan B, Olmedilla B, Granado F, Blanco I, et al. A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. Br J Nutr. 2001;85(4):499–507.CrossRefGoogle Scholar
  4. 4.
    Rao AV, Waseem Z, Agarwal S. Lycopene content of tomatoes and tomato products and their contribution to dietary lycopene. Food Res Int. 1998;31(10):737–41.CrossRefGoogle Scholar
  5. 5.
    Suwanaruang T. Analyzing lycopene content in fruits. Agric Agric Sci Proc. 2016;11:46–8.Google Scholar
  6. 6.
    Milani C, Maccari M, Mosconi P. Action of lycopene in the experimental gastric ulcer. Pharmacology. 1970;4(6):334–40.CrossRefGoogle Scholar
  7. 7.
    Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys. 1989;274(2):532–8.CrossRefGoogle Scholar
  8. 8.
    Costa-Rodrigues J, Pinho O, Monteiro PRR. Can lycopene be considered an effective protection against cardiovascular disease? Food Chem. 2018;245:1148–53.CrossRefGoogle Scholar
  9. 9.
    Thies F, Masson LF, Rudd A, Vaughan N, Tsang C, Brittenden J, et al. Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. Am J Clin Nutr. 2012;95(5):1013–22.CrossRefGoogle Scholar
  10. 10.
    Karppi J, Kurl S, Ronkainen K, Kauhanen J, Laukkanen JA. Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men. PLoS ONE. 2013;8(5):e64107.CrossRefGoogle Scholar
  11. 11.
    Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retino in relation to risk of prostate cancer. JNCI J Natl Cancer Inst. 1995;87(23):1767–76.CrossRefGoogle Scholar
  12. 12.
    Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, et al. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. JNCI J Natl Cancer Inst. 2014;106(2):430.CrossRefGoogle Scholar
  13. 13.
    King-Batoon A, Leszczynska JM, Klein CB. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ Mol Mutagen. 2008;49(1):36–45.CrossRefGoogle Scholar
  14. 14.
    Palozza P, Simone RE, Catalano A, Mele MC. Tomato lycopene and lung cancer prevention: from experimental to human studies. Cancers. 2011;3(2):2333–57.CrossRefGoogle Scholar
  15. 15.
    Vecchia CL. Tomatoes, lycopene intake, and digestive tract and female hormone-related neoplasms. Exp Biol Med. 2002;227(10):860–3.CrossRefGoogle Scholar
  16. 16.
    Nkondjock A, Ghadirian P, Johnson KC, Krewski D. Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr. 2005;135(3):592–7.CrossRefGoogle Scholar
  17. 17.
    Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of carotenes and xanthophylls. FEBS Lett. 1996;384(3):240–2.CrossRefGoogle Scholar
  18. 18.
    Stahl W, Junghans A, de Boer B, Driomina ES, Briviba K, Sies H. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. FEBS Lett. 1998;427(2):305–8.CrossRefGoogle Scholar
  19. 19.
    Sahin K, Kucuk O. Lycopene in cancer prevention. In: Ramawat KG, Merillon JM, editors. Natural products: phytochemistry, botany and metabolism of alkaloids, phenolics and terpenes. Berlin: Springer; 2013. p. 3875–3922.  https://doi.org/10.1007/978-3-642-22144-6.CrossRefGoogle Scholar
  20. 20.
    Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res. 2016;30(5):691–700.CrossRefGoogle Scholar
  21. 21.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193(1):265–75.Google Scholar
  22. 22.
    Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. II. J Biol Chem. 1964;239:2379–85.PubMedGoogle Scholar
  23. 23.
    Wójcikowski J, Gołembiowska K, Daniel WA. Regulation of liver cytochrome P450 by activation of brain dopaminergic system: physiological and pharmacological implications. Biochem Pharmacol. 2008;76(2):258–67.CrossRefGoogle Scholar
  24. 24.
    Dovrtelova G, Zendulka O, Noskova K, Jurica J, Pes O, Dusek J, et al. Effect of endocannabinoid oleamide on rat and human liver cytochrome P450 enzymes in in vitro and in vivo models. Drug Metab Dispos. 2018;46:913–23.CrossRefGoogle Scholar
  25. 25.
    Dovrtelova G, Noskova K, Jurica J, Turjap M, Zendulka O. Can bioactive compounds of Crocus sativus L. Influence the metabolic activity of selected CYP enzymes in the rat? Physiol Res. 2015;64:S453–8.PubMedGoogle Scholar
  26. 26.
    Noskova K, Dovrtelova G, Zendulka O, Remínek R, Jurica J. The effect of (−)-linalool on the metabolic activity of liver CYP enzymes in rats. Physiol Res. 2016;65:6.Google Scholar
  27. 27.
    Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, Sellers EM. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos. 1999;27(8):924–30.PubMedGoogle Scholar
  28. 28.
    Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol. 2002;63(5):889–96.CrossRefGoogle Scholar
  29. 29.
    Rowles JL, Ranard KM, Applegate CC, Jeon S, An R, Erdman JW. Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:319–36.CrossRefGoogle Scholar
  30. 30.
    Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration’s Evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. JNCI J Natl Cancer Inst. 2007;99(14):1074–85.CrossRefGoogle Scholar
  31. 31.
    Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Prev Biomark. 2001;10(8):861–8.Google Scholar
  32. 32.
    Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med. 2002;227(10):881–5.CrossRefGoogle Scholar
  33. 33.
    Leoncini E, Nedovic D, Panic N, Pastorino R, Edefonti V, Boccia S. Carotenoid intake from natural sources and head and neck cancer: a systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol Prev Biomark. 2015;24(7):1003–11.CrossRefGoogle Scholar
  34. 34.
    Crooker K, Aliani R, Ananth M, Arnold L, Anant S, Thomas SM. A review of promising natural chemopreventive agents for head and neck cancer. Cancer Prev Res. 2018;11(8):441–50.CrossRefGoogle Scholar
  35. 35.
    Gullett NP, Ruhul Amin ARM, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol. 2010;37(3):258–81.CrossRefGoogle Scholar
  36. 36.
    Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, et al. Lycopene enhances Docetaxel’s effect in castration-resistant prostate cancer associated with insulin-like growth factor i receptor levels. Neoplasia. 2011;13(2):108–19.CrossRefGoogle Scholar
  37. 37.
    Kong L, Song C, Ye L, Xu J, Guo D, Shi Q. The effect of lycopene on cytochrome P450 isoenzymes and P-glycoprotein by using human liver microsomes and Caco-2 cell monolayer model. Int J Food Sci Nutr. 2018;69(7):835–41.CrossRefGoogle Scholar
  38. 38.
    Jewell C, O’Brien NM. Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat. Br J Nutr. 1999;81(3):235–42.CrossRefGoogle Scholar
  39. 39.
    Porrini M, Riso P. What are typical lycopene intakes? J Nutr. 2005;135(8):2042S–5S.CrossRefGoogle Scholar

Copyright information

© Maj Institute of Pharmacology Polish Academy of Sciences 2020

Authors and Affiliations

  • Kristýna Nosková
    • 1
  • Gabriela Dovrtělová
    • 2
  • Ondřej Zendulka
    • 1
  • Markéta Strakošová
    • 1
  • Ondřej Peš
    • 3
  • Jan Juřica
    • 1
    • 4
    • 5
    Email author
  1. 1.Department of Pharmacology, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  2. 2.RECETOX CentreMasaryk UniversityBrnoCzech Republic
  3. 3.Department of Biochemistry, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  4. 4.Masaryk Memorial Cancer InstituteBrnoCzech Republic
  5. 5.Department of Human Pharmacology and Toxicology, Faculty of PharmacyUniversity of Veterinary and Pharmaceutical SciencesBrnoCzech Republic

Personalised recommendations